Valentina Agostina
Private-Equity-Analyst bei TVM Life Science Management, Inc.
Ursprung des Netzwerks ersten Grades von Valentina Agostina
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
TVM Life Science Management, Inc.
2
| Subsidiary | Investment Managers | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Valentina Agostina
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
University of Ottawa | College/University | Undergraduate Degree Undergraduate Degree | |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Biotechnology | Director/Board Member Director/Board Member | |
ACER THERAPEUTICS INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Rotman School of Management | College/University | Masters Business Admin | |
Panthera Dental Inc.
Panthera Dental Inc. Medical SpecialtiesHealth Technology Panthera Dental Inc. engages in prosthetic implant solutions and dental sleep appliances. Its products include metal implant bar, integrated bar, diamart, ReBourke, Copywax, Angulated Screw Channel, and Components and Attachment. The company was founded by Bernard Robichaud, Gabriel Robichaud, and Beatrice Robichaud in 2011 and is headquartered in Quebec, Canada. | Medical Specialties | Director/Board Member | |
Emovi, Inc.
Emovi, Inc. Medical/Nursing ServicesHealth Services Emovi, Inc. offers orthopedic services. It offers services to people suffering from knee osteoarthritis, ligament or meniscus tears, patello-femoral syndrome, tendonitis, and biomechanical deficiencies causing pain and disability. The company was founded in 2002 and is headquartered in Montr?al, Canada. | Medical/Nursing Services | Director/Board Member | |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Medical Specialties | Director/Board Member | |
McGill University | College/University | Doctorate Degree | |
Interface Biologics, Inc.
Interface Biologics, Inc. Information Technology ServicesTechnology Services Interface Biologics, Inc. operates as a commercial stage privately held company that develops transformative biomedical polymer technologies to improve the safety and effectiveness of medical devices. It provides technologies to medical device manufacturers and drug companies. The company was founded by Paul J. Santerre in December 2001 and is headquartered in Toronto, Canada. | Information Technology Services | Director/Board Member | |
Azelon Pharmaceuticals, Inc.
Azelon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA. | Pharmaceuticals: Major | Director/Board Member | |
Kaneq Bioscience Ltd.
Kaneq Bioscience Ltd. BiotechnologyHealth Technology Kaneq Bioscience Ltd. operates as a biotechnology company focuses on developing treatments for type 2 diabetes. The firm develops a protein tyrosine phosphatase1B inhibitor for treating type 2 diabetes mellitus. The company was founded by Jean Bourgouin on October 19, 2012 and is headquartered in Montreal, Canada. | Biotechnology | Director/Board Member | |
Technologies Morphocell, Inc.
Technologies Morphocell, Inc. BiotechnologyHealth Technology Morphocell Technologies, Inc. aims to transform the treatment of severe liver diseases through cell therapy. The company is based in Laval, Canada. The Canadian company is developing stem cell-derived engineered liver tissues to replace liver functions and treat various forms of liver disease. Morphocell Technologies was founded in 2018 by Margaret Bywater Ekegard, Massimiliano Paganelli, and Raggi Claudia. Massimiliano Paganelli has been the CEO of the company since 2019. | Biotechnology | Director/Board Member | |
Delta TpX, Inc.
Delta TpX, Inc. Pharmaceuticals: OtherHealth Technology Delta TpX, Inc. develops oncology therapeutics. The American company was founded by Everett Stone, Aaron Schuchart, Cynthia Lavoie, David G. Lowe. David G. Lowe has been the CEO since incorporation. | Pharmaceuticals: Other | Founder | |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
FAAH Pharma, Inc.
FAAH Pharma, Inc. BiotechnologyHealth Technology FAAH Pharma, Inc. operates as a project-focused company developing a clinical asset initially for postherpetic neuralgia. The company was founded on June 26, 2014 and is headquartered in Montreal, Canada. | Biotechnology | Chairman | |
RAPID MICRO BIOSYSTEMS, INC. | Industrial Machinery | Director/Board Member | |
PROFOUND MEDICAL CORP. | Medical Specialties | Director/Board Member | |
AllosteRx Capital Management (Canada), Inc. | Chief Executive Officer | ||
CCRM Enterprises Inc | President | ||
Fibrocor Therapeutics LP
Fibrocor Therapeutics LP Miscellaneous Commercial ServicesCommercial Services Fibrocor Therapeutics LP is a privately held Canadian drug discovery company that is pioneering the use of tissue-specific therapeutics in the field of precision medicine, particularly in fibrosis. The company is based in Toronto, Canada. The company aims to improve the lives of patients by delivering transformative treatments that tackle the root causes of fibrosis, leading to better outcomes and enhanced quality of life. Fibrocor leverages its extensive expertise and one of the largest patient-derived clinically annotated biorepositories of fibrotic tissue to refine and validate therapeutic candidates, ensuring they meet the highest standards of efficacy and safety. | Miscellaneous Commercial Services | Director/Board Member | |
VG Partners
VG Partners Investment ManagersFinance VG Partners is a private equity investment firm. The private company is based in Toronto, Canada. and has subsidiaries in Canada. | Investment Managers | Corporate Officer/Principal | |
Lumira Capital Investment Management, Inc.
Lumira Capital Investment Management, Inc. Investment ManagersFinance Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto. | Investment Managers | Private Equity Investor | |
AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
University of Toronto | College/University | Doctorate Degree | |
Cita NeuroPharmaceuticals, Inc.
Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Director/Board Member | |
LymphoSign, Inc.
LymphoSign, Inc. BiotechnologyHealth Technology LymphoSign, Inc. develops drugs for the cancer treatment. It also develops drugs acting on signaling pathways involved in the progression of acute leukemias, lymphomas and solid tumors. The company was founded by Chaim Roifman in 2000 and is headquartered in Markham, Canada. | Biotechnology | Director/Board Member | |
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Ixchelsis Ltd. develops oxytocin receptor antagonist for the treatment of premature ejaculation. It operates as a biotechnology company. The firm's product in pipeline IX-01 treats the male sexual health indication and premature ejaculation. The company was founded on July 27, 2011 by Gary John Muirhead, Lizbeth Anne Littlewood, Ian Howard Osterloh and Karl Richard Gibson and is headquartered in Sandwich, the United Kingdom. | Biotechnology | Director/Board Member | |
Queen's University | College/University | Graduate Degree | |
COLUCID PHARMACEUTICALS INC | Biotechnology | Director/Board Member | |
Modulate Therapeutics, Inc.
Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Modulate Therapeutics, Inc. develops a medicine compound designed to re-engage the immune system in order to recognize and eradicate neoplastic disease. The company was founded by September 29, 2015 and is headquartered in Montréal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Albireo AB
Albireo AB Pharmaceuticals: MajorHealth Technology Albireo AB operates as a biopharmaceutical company, which focuses on the development and potential commercialization of novel bile acid modulators. It helps treat orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions for which there is high unmet need. The company was founded by Per-Göran Gillberg and Jan Mattsson and is headquartered in Göteborg, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
AurKa Pharma, Inc.
AurKa Pharma, Inc. BiotechnologyHealth Technology AurKa Pharma, Inc. develops medication for cancer treatment. The company was founded by Caroline Fortier and is headquartered in Montreal, Canada. | Biotechnology | Director/Board Member | |
CDP Capital Private Equity
CDP Capital Private Equity Investment ManagersFinance CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London. | Investment Managers | President | |
Apiary Therapeutics, Inc. | Director/Board Member |
Statistik
International
Kanada | 33 |
Vereinigte Staaten | 12 |
Vereinigtes Königreich | 2 |
Schweden | 2 |
Sektoral
Health Technology | 26 |
Finance | 7 |
Consumer Services | 6 |
Commercial Services | 3 |
Health Services | 3 |
Operativ
Director/Board Member | 36 |
Private Equity Investor | 4 |
Corporate Officer/Principal | 4 |
Independent Dir/Board Member | 3 |
President | 3 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Luc Marengère | 31 |
Cynthia Lavoie | 23 |
- Börse
- Insiders
- Valentina Agostina
- Unternehmensverbindungen